Association between change of health care providers and pregnancy exposure to FDA category C, D and X drugs.
- Author:
Jianzhou YANG
1
,
2
,
3
,
4
;
Rihua XIE
5
;
Daniel KREWSKI
6
;
Yongjin WANG
7
;
Mark WALKER
5
;
Wenjun CAO
8
;
Shi Wu WEN
1
;
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Continuity of Patient Care; Databases, Factual; Drug Prescriptions; statistics & numerical data; Drug Utilization; statistics & numerical data; Female; Health Personnel; Humans; Logistic Models; Pharmaceutical Preparations; Pregnancy; drug effects; Saskatchewan; United States; United States Food and Drug Administration
- From: Chinese Medical Journal 2014;127(4):702-706
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDChanging health care providers frequently breaks the continuity of care, which is associated with many health care problems. The purpose of this study was to examine the association between a change of health care providers and pregnancy exposure to FDA category C, D and X drugs.
METHODSA 50% random sample of women who gave a birth in Saskatchewan between January 1, 1997 and December 31, 2000 were chosen for this study. The association between the number of changes in health care providers and with pregnancy exposure to category C, D, and X drugs for those women with and without chronic diseases were evaluated using multiple logistical regression, with adjusted odds ratios (ORs) and its 95% confidence intervals (CIs) as the association measures.
RESULTSA total of 18 568 women were included in this study. Rates of FDA C, D, and X drug uses were 14.35%, 17.07%, 21.72%, and 31.14%, in women with no change of provider, 1-2 changes, 3-5 changes, and more than 5 changes of health care providers. An association between the number of changes of health care providers and pregnancy exposure to FDA C, D, and X drugs existed in women without chronic diseases but not in women with chronic disease.
CONCLUSIONChange of health care providers is associated with pregnancy exposure to FDA category C, D and X drugs in women without chronic diseases.